Ubs Asset Management Americas Inc Moon Lake Immunotherapeutics Transaction History
Ubs Asset Management Americas Inc
- $277 Billion
- Q1 2024
A detailed history of Ubs Asset Management Americas Inc transactions in Moon Lake Immunotherapeutics stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 15,231 shares of MLTX stock, worth $642,748. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,231
Previous 15,231
-0.0%
Holding current value
$642,748
Previous $919,000
16.76%
% of portfolio
0.0%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding MLTX
# of Institutions
135Shares Held
56MCall Options Held
379KPut Options Held
402K-
Bvf Inc San Francisco, CA21.8MShares$918 Million32.73% of portfolio
-
Cormorant Asset Management, LP Boston, MA8.49MShares$358 Million24.56% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.58MShares$109 Million1.56% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.31MShares$97.5 Million0.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.28MShares$96.4 Million0.23% of portfolio
About MoonLake Immunotherapeutics
- Ticker MLTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 36,925,600
- Market Cap $1.56B
- Description
- MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It is developing Sonelokimab, a novel investigational Nanobody therapy for the treatment of inflammation. The company is involved in conducting Phase II trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, or rad...